Rimegepant sulfate is the sulfate salt form of rimegepant, a selective calcitonin gene-related peptide (CGRP) receptor antagonist. As a specialty chemical and active pharmaceutical ingredient (API), it is primarily used in the development and manufacturing of medications for the acute treatment of migraine in adults. By blocking CGRP receptors, it interrupts migraine pain signaling pathways, providing rapid relief from symptoms such as headache, nausea, photophobia, and phonophobia. This compound is supplied as a high-purity white to off-white powder (≥99.5% purity), suitable for pharmaceutical formulation into orally disintegrating tablets or other dosage forms. Ongoing research explores its potential for migraine prevention, highlighting its versatility in neurological therapeutics. It represents a targeted alternative to traditional analgesics and triptans, especially for patients with contraindications to those therapies.